Quick Answer
ROCKET PHARMACEUTICALS, INC. reported R&D Expense of $142.01 million for fiscal year 2025.
ROCKET PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $142.01M | -17.1% |
| 2024 | $171.24M | -8.1% |
| 2023 | $186.34M | +12.5% |
| 2022 | $165.57M | +32.0% |
| 2021 | $125.48M | +19.0% |
| 2020 | $105.44M | +82.1% |
| 2019 | $57.91M | +8.7% |
| 2018 | $53.27M | +257.1% |
| 2017 | $14.92M | +148.9% |
| 2016 | $5.99M | -52.3% |
| 2015 | $12.55M | +124.5% |
| 2014 | $5.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $34.07M | -19.5% | -20.1% |
| June 30, 2025 | $42.66M | -8.0% | +18.7% |
| March 31, 2025 | $35.94M | -20.5% | -15.1% |
| September 30, 2024 | $42.31M | -9.7% | -8.7% |
| June 30, 2024 | $46.34M | -9.8% | +2.5% |
| March 31, 2024 | $45.23M | -2.5% | -3.5% |
| September 30, 2023 | $46.84M | +8.0% | -8.8% |
| June 30, 2023 | $51.38M | +24.2% | +10.8% |
- ROCKET PHARMACEUTICALS, INC. showed a decrease of -17.1% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, ROCKET PHARMACEUTICALS, INC.’s r&d expense has grown by 2439.6% (from $5.59 million to $142.01 million).
- The most recent figure is from ROCKET PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: